Parkinson’s prevalence expected to increase by 18% by 2025

Patient recruitment started and first patient consented in the CDNF Phase I-II clinical study

TreatER Horizon 2020 program website launched

How wearable devices can help people with Parkinson’s communicate better with their doctors

200 years of Parkinson’s disease: still no cure, but EU policy must drive improvements in quality of life

World Parkinson’s Day: #Unite for Parkinsons social media campaign

Herantis Pharma’s clinical study with CDNF in Parkinson’s disease authorized in Sweden

Herantis Pharma’s Parkinson study wins EUR 6.0 million grant from the European Union Horizon 2020 program